Similar articles

• Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial.

  APEX AMI Investigators; Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes D Jr, O'Neill WW, Todaro TG, Vahanian A, Van de Werf F. APEX AMI Investigators, et al. JAMA. 2007 Jan 3;297(1):43-51. doi: 10.1001/jama.297.1.43. JAMA. 2007. PMID: 17200474 Clinical Trial.
• Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.

  Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau JC, Ruzyllo W, Armstrong PW; COMMA Investigators. Granger CB, et al. Circulation. 2003 Sep 9;108(10):1184-90. doi: 10.1161/01.CIR.0000087447.12918.85. Epub 2003 Aug 18. Circulation. 2003. PMID: 12925454 Clinical Trial.
• Pexelizumab and the APEX AMI trial.

  Armstrong PW, Granger CB. Armstrong PW, et al. JAMA. 2007 May 2;297(17):1881; author reply 1881-2. doi: 10.1001/jama.297.17.1881-b. JAMA. 2007. PMID: 17473297 No abstract available.
• Pexelizumab and its role in the treatment of myocardial infarction and in coronary artery bypass graft surgery: a review.

  Patel JA, Ghatak SB. Patel JA, et al. Recent Pat Cardiovasc Drug Discov. 2008 Jun;3(2):145-52. doi: 10.2174/157489008784705322. Recent Pat Cardiovasc Drug Discov. 2008. PMID: 18537766 Review.
• Pexelizumab: a novel therapy for myocardial ischemia-reperfusion.

  Patel MR, Granger CB. Patel MR, et al. Drugs Today (Barc). 2005 Mar;41(3):165-70. doi: 10.1358/dot.2005.41.3.892521. Drugs Today (Barc). 2005. PMID: 15883613 Review.